GlaxoSmithKline plc and Theravance Inc. achieved major milestones this week in a pair of clinical development programs focused on treatments for patients with chronic obstructive pulmonary disease (COPD). Read More
Inspiration Pharmaceuticals Inc., of Laguna Niguel, Calif., said results from the Phase I portion of an ongoing IB1001 study demonstrated noninferiority of the drug in achieving overall levels of replacement factor compared to BeneFIX, an approved recombinant FIX product for hemophilia B marketed by New York-based Pfizer Inc. Those data were presented at the European Association for Haemophilia and Allied Disorders meeting in Geneva. Read More
Pacira Pharmaceuticals Inc.'s $42 million initial public offering – the first biotech IPO out of the gate in 2011 – looks a lot like the pricings of 2010. Read More
Ziopharm Oncology Inc. could raise as much as $63.5 million through an underwritten public offering of 9.6 million shares of common stock priced at $5.75 per share – about 7 percent below Wednesday's closing price – and an underwriter's 30-day option to purchase as many as 1.4 million additional shares. Read More
Digna Biotech SL, of Madrid, Spain, and the Centro de Investigacion Medica Aplicada de la Universidad de Navarra said the European Union finalized a €3.3 million (US$4.5 million) grant to AIPGENE consortium and, as members of the consortium, Digna and CIMA will receive €500,000 and €800,000, respectively, for the clinical development of a gene therapy product for acute intermittent porphyria. As part of the grant, they will complete a Phase I/II study, with patient enrollment slated to start in early 2012. Read More
